temozolomide has been researched along with Experimental Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stevens, MF | 1 |
| Hickman, JA | 1 |
| Stone, R | 1 |
| Gibson, NW | 1 |
| Baig, GU | 1 |
| Lunt, E | 1 |
| Newton, CG | 1 |
| Braun, CJ | 1 |
| Bruno, PM | 1 |
| Horlbeck, MA | 1 |
| Gilbert, LA | 1 |
| Weissman, JS | 1 |
| Hemann, MT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075] | Phase 2 | 25 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00582075)
Timeframe: 2 years
| Intervention | weeks (Median) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 31 |
Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 37 |
2 other studies available for temozolomide and Experimental Leukemia
| Article | Year |
|---|---|
Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Imidazoles; Leukemia, Experimental; M | 1984 |
Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Imidazoles; Leukemia, Experimental; M | 1984 |
Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Imidazoles; Leukemia, Experimental; M | 1984 |
Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Imidazoles; Leukemia, Experimental; M | 1984 |
Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation.
Topics: Animals; Bacterial Proteins; CRISPR-Associated Protein 9; Dacarbazine; DNA Damage; DNA Modification | 2016 |